Read news on cell lymphoma with our app.
Read more in the app
Massey becomes first U.S. site to enroll patients in global Phase 2a trial of first-in-class therapy for T-cell lymphoma - EurekAlert!
New cellular immunotherapy approach shows promise for B-cell lymphoma - EurekAlert
Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma - EurekAlert
Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma
Researchers uncover mechanism that fuels growth of aggressive B-cell lymphoma
Novel therapeutic bispecific antibodies for B-cell lymphoma - EurekAlert
